USP22 controls iNKT immunity through MED1 suppression of histone H2A monoubiquitination
JOURNAL OF EXPERIMENTAL MEDICINE
Authors: Zhang, Yana; Wang, Yajun; Gao, Beixue; Sun, Yueqi; Cao, Liang; Genardi, Samantha M.; Wang, Chyung-Ru; Li, HuaBin; Sun, Zhaolin; Yang, Yanjie; Fang, Deyu
Abstract
The ubiquitin pathway has been shown to regulate iNKT cell immunity, but the deubiquitinase involved in this process has not been identified. Herein we found that ubiquitin-specific peptidase 22 (USP22) is highly expressed in iNKT cells during their early developmental stage 1. USP22 deficiency blocked the transition from stage 1 to 2 during iNKT cell development in a cellintrinsic manner. USP22 suppression also diminishes iNKT17 and iNKT1 differentiation but favors iNKT2 polarization without altering conventional T cell activation and differentiation. USP22 interacts with the Mediator complex subunit 1 (MED1), a transcription coactivator involved in iNKT cell development. Interestingly, while interacting with MED1, USP22 does not function as a deubiquitinase to suppress MED1 ubiquitination for its stabilization. Instead, USP22 enhances MED1 functions for IL-2R beta and T-bet gene expression through deubiquitinating histone H2A but not H2B monoubiquitination. Therefore, our study revealed USP22-mediated histone H2A deubiquitination fine-tunes MED1 transcriptional activation as a previously unappreciated molecular mechanism to control iNKT development and functions.
A novel histone H4 variant H4G regulates rDNA transcription in breast cancer
NUCLEIC ACIDS RESEARCH
Authors: Long, Mengping; Sun, Xulun; Shi, Wenjin; Yanru, An; Leung, Sophia T. C.; Ding, Dongbo; Cheema, Manjinder S.; MacPherson, Nicol; Nelson, Christopher J.; Ausio, Juan; Yan, Yan; Ishibashi, Toyotaka
Abstract
Histone variants, present in various cell types and tissues, are known to exhibit different functions. For example, histone H3.3 and H2A.Z are both involved in gene expression regulation, whereas H2A.X is a specific variant that responds to DNA double-strand breaks. In this study, we characterized H4G, a novel hominidae-specific histone H4 variant. We found that H4G is expressed in a variety of human cell lines and exhibit tumor-stage dependent overexpression in tissues from breast cancer patients. We found that H4G localized primarily to the nucleoli of the cell nucleus. This localization was controlled by the interaction of the alpha-helix 3 of the histone fold motif with a histone chaperone, nucleophosmin 1. In addition, we found that modulating H4G expression affects rRNA expression levels, protein synthesis rates and cell-cycle progression. Our data suggest that H4G expression alters nucleolar chromatin in a way that enhances rDNA transcription in breast cancer tissues.